PARP1 and prostate carcinoma: In this study, we showed that the levels of procaspases-3, -8, and -9, Bid, and Bcl-2 decreased and the levels of cleaved-PARP and Bax increased in prostate cancer RC-58T cells following sanggenol L treatment (Figure 3A,C).